Correction to: Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism

Correction to: J Ovarian Res 14, 97 (2021)

https://doi.org/10.1186/s13048-021-00847-4

In the original publication of this article [1], the legend for Figs. 1 and 2 were missing. The correct figures are shown here. The original article has been corrected.

Fig. 1.

ROC curve analysis of SFRP5 for total PCOS. In all PCOS population, the SFRP5 cut-off value was 46.13 ng/ml (AUC 0.960; 95% CI 0.900–0.989; P < 0.0001) to identify PCOS with a sensitivity of 88.06% and specificity of 96.87%. The AMH cut-off value was 3.23 ng/ml (AUC 0.968; 95% CI 0.912–0.993; P < 0.0001) with a sensitivity of 98.51% and specificity of 90.62%. The AUC of combination of SFRP5 and AMH was 0.980 with a sensitivity of 91.04% and specificity of 100% (95% CI 0.930–0.998; P < 0.0001). AUC: area under the curve, ROC: receiver operating characteristic analysis

Fig. 2.

ROC curve analysis of SFRP5 for PCOS with AMH < 4.7 ng/ml. In PCOS with AMH < 4.7 ng/ml, the SFRP5 cut-off value was 42.69 ng/ml (AUC, 0.955; 95% CI 0.864–0.992; P < 0.0001) to identify PCOS with a sensitivity of 82.61% and specificity of 96.97%. AUC: area under the curve, ROC: receiver operating characteristic analysis